Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Market Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides" has been added to ...
-
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute...
-
PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around...
-
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
-
Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Peanut Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ...
-
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pollen Allergy was valued...
-
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with...
-
Intrommune welcomes an independent editorial that was recently published in Annals of Allergy, Asthma & Immunology.
-
Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project led by Dr. Sheila Singh and her team at McMaster University. The project...
-
Lumanity announces a new partnership to accelerate the lab to bedside journey for cancer patients with the Parker Institute for Cancer Immunotherapy.